Download PDF
kleintier konkret 2018; 21(S 03): 3-12
DOI: 10.1055/a-0662-1148
Hund
Dermatologie
Georg Thieme Verlag KG Stuttgart · New York

Neue Entwicklungen bei der Behandlung atopischer Hunde

Natalie K. Y. Gedon
,
Ralf S. Müller
Further Information

Publication History

Publication Date:
27 September 2018 (online)

Also available at
    Permissions and Reprints All articles of this category

Die atopische Dermatitis (AD) beim Hund kommt in der Kleintierpraxis sehr häufig vor. Im Rahmen dieses Artikels werden die bisherigen Behandlungsoptionen, die neuen Therapieansätze sowie das Management der atopischen Patienten und deren Besitzer ausführlich beschrieben.

Literaturverzeichnis als PDF

 

  • Literatur

  • 1 Saridomichelakis MN, Olivry T. An update on the treatment of canine atopic dermatitis. Vet J 2016; 207: 29-37
    CrossrefPubMedGoogle Scholar
  • 2 Saridomichelakis MN, Koutinas AF, Gioulekas D. et al. Canine atopic dermatitis in Greece: clinical observations and the prevalence of positive intradermal test reactions in 91 spontaneous cases. Vet Immunol Immunopathol 1999; 69 (01) 61-73
    CrossrefPubMedGoogle Scholar
  • 3 Olivry T, Mueller RS. International Task Force on Canine Atopic D. Evidence-based veterinary dermatology: a systematic review of the pharmacotherapy of canine atopic dermatitis. Vet Dermatol 2003; 14 (03) 121-146
    CrossrefPubMedGoogle Scholar
  • 4 Olivry T, DeBoer DJ, Favrot C. et al. Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA). BMC Vet Res 2015; 11: 210
    CrossrefPubMedGoogle Scholar
  • 5 Nuttall T, Mueller R, Bensignor E. et al. Efficacy of a 0.0584 % hydrocortisone aceponate spray in the management of canine atopic dermatitis: a randomised, double blind, placebo-controlled trial. Vet Dermatol 2009; 20 (03) 191-198
    CrossrefPubMedGoogle Scholar
  • 6 Nuttall TJ, McEwan NA, Bensignor E. et al. Comparable efficacy of a topical 0.0584 % hydrocortisone aceponate spray and oral ciclosporin in treating canine atopic dermatitis. Vet Dermatol 2012; 23 (01) 4-10 e1–2
    CrossrefPubMedGoogle Scholar
  • 7 Marsella R, Nicklin CF, Saglio S. et al. Investigation on the clinical efficacy and safety of 0.1 % tacrolimus ointment (Protopic) in canine atopic dermatitis: a randomized, double-blinded, placebo-controlled, cross-over study. Vet Dermatol 2004; 15 (05) 294-303
    CrossrefPubMedGoogle Scholar
  • 8 Bensignor E, Olivry T. Treatment of localized lesions of canine atopic dermatitis with tacrolimus ointment: a blinded randomized controlled trial. Vet Dermatol 2005; 16 (01) 52-60
    CrossrefPubMedGoogle Scholar
  • 9 Saevik BK, Bergvall K, Holm BR. et al. A randomized, controlled study to evaluate the steroid sparing effect of essential fatty acid supplementation in the treatment of canine atopic dermatitis. Vet Dermatol 2004; 15 (03) 137-145
    CrossrefPubMedGoogle Scholar
  • 10 Muller MR, Linek M, Lowenstein C. et al. Evaluation of cyclosporine-sparing effects of polyunsaturated fatty acids in the treatment of canine atopic dermatitis. Vet J 2016; 210: 77-81
    CrossrefPubMedGoogle Scholar
  • 11 Olivry T, DeBoer DJ, Favrot C. et al. Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis. Vet Dermatol 2010; 21 (03) 233-248
    CrossrefPubMedGoogle Scholar
  • 12 DeBoer DJ, Griffin CE. The ACVD task force on canine atopic dermatitis (XXI): antihistamine pharmacotherapy. Vet Immunol Immunopathol 2001; 81(3 – 4): 323-329
    CrossrefPubMedGoogle Scholar
  • 13 Bizikova P, Papich MG, Olivry T. Hydroxyzine and cetirizine pharmacokinetics and pharmacodynamics after oral and intravenous administration of hydroxyzine to healthy dogs. Vet Dermatol 2008; 19 (06) 348-357
    CrossrefPubMedGoogle Scholar
  • 14 Eichenseer M, Johansen C, Mueller RS. Efficacy of dimetinden and hydroxyzine/chlorpheniramine in atopic dogs: a randomised, controlled, double-blinded trial. Vet Rec 2013; 173 (17) 423
    CrossrefPubMedGoogle Scholar
  • 15 Steffan J, Parks C, Seewald W. North American Veterinary Dermatology Cyclosporine Study G. Clinical trial evaluating the efficacy and safety of cyclosporine in dogs with atopic dermatitis. J Am Vet Med Assoc 2005; 226 (11) 1855-1863
    CrossrefPubMedGoogle Scholar
  • 16 Nuttall T, Reece D, Roberts E. Life-long diseases need life-long treatment: long-term safety of ciclosporin in canine atopic dermatitis. Vet Rec 2014; 174 Suppl 2: 3-12
    CrossrefPubMedGoogle Scholar
  • 17 Kovalik M, Thoday KL, van den Broek AH. The use of ciclosporin A in veterinary dermatology. Vet J 2012; 193 (02) 317-325
    CrossrefPubMedGoogle Scholar
  • 18 Gonzales AJ, Bowman JW, Fici GJ. et al. Oclacitinib (APOQUEL((R))) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Ther 2014; 37 (04) 317-324
    CrossrefPubMedGoogle Scholar
  • 19 Little PR, King VL, Davis KR. et al. A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs. Vet Dermatol 2015; 26 (01) 23-30 e7–8
    CrossrefPubMedGoogle Scholar
  • 20 Cosgrove SB, Wren JA, Cleaver DM. et al. A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel(R)) in client-owned dogs with atopic dermatitis. Vet Dermatol 2013; 24 (06) 587-597 e141–142
    CrossrefPubMedGoogle Scholar
  • 21 Cosgrove SB, Cleaver DM, King VL. et al. Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life. Vet Dermatol 2015; 26 (03) 171-179 e35
    CrossrefPubMedGoogle Scholar
  • 22 Simpson AC, Schissler JR, Rosychuk RAW. et al. The frequency of urinary tract infection and subclinical bacteriuria in dogs with allergic dermatitis treated with oclacitinib: a prospective study. Vet Dermatol 2017; 28 (05) 485-e113
    PubMedGoogle Scholar
  • 23 Fukuyama T, Ganchingco JR, Baumer W. Demonstration of rebound phenomenon following abrupt withdrawal of the JAK1 inhibitor oclacitinib. Eur J Pharmacol 2017; 794: 20-26
    CrossrefPubMedGoogle Scholar
  • 24 Gadeyne C, Little P, King VL. et al. Efficacy of oclacitinib (Apoquel(R)) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia. Vet Dermatol 2014; 25 (06) 512-518 e86
    CrossrefPubMedGoogle Scholar
  • 25 McCandless EE, Rugg CA, Fici GJ. et al. Allergen-induced production of IL-31 by canine Th2 cells and identification of immune, skin, and neuronal target cells. Vet Immunol Immunopathol 2014; 157(1 – 2): 42-48
    CrossrefPubMedGoogle Scholar
  • 26 Michels GM, Ramsey DS. et al. A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody in client owned dogs with atopic dermatitis. Vet Dermatol 2016; 27 (06) 478-e129
    PubMedGoogle Scholar
  • 27 Marsella R, Ahrens K, Sanford R. Investigation of the correlation of serum IL-31 with severity of dermatitis in an experimental model of canine atopic dermatitis using beagle dogs. Vet Dermatol 2018; 29 (01) 69-e28
    PubMedGoogle Scholar
  • 28 Michels GM, Walsh KF, Kryda KA. et al. A blinded, randomized, placebo-controlled trial of the safety of lokivetmab (ZTS-00103289), a caninized anti-canine IL-31 monoclonal antibody in client-owned dogs with atopic dermatitis. Vet Dermatol 2016; 27 (06) 505-e136
    PubMedGoogle Scholar
  • 29 Moyaert H, Van Brussel L, Borowski S. et al. A blinded, randomized clinical trial evaluating the efficacy and safety of lokivetmab compared to ciclosporin in client-owned dogs with atopic dermatitis. Vet Dermatol 2017; 28 (06) 593-e145
    PubMedGoogle Scholar
  • 30 Bachmann MF, Zeltins A, Kalnins G. et al. Vaccination against IL-31 for the treatment of atopic dermatitis in dogs. J Allergy Clin Immunol 2018; 142 (01) 279-281.e1
    CrossrefPubMedGoogle Scholar
  • 31 Klinger CJ, Hobi S, Johansen C. et al. Vitamin D shows in vivo efficacy in a placebo-controlled, double-blinded, randomised clinical trial on canine atopic dermatitis. Vet Rec 2018; 182 (14) 406
    CrossrefPubMedGoogle Scholar
  • 32 Loewenstein C, Mueller RS. A review of allergen-specific immunotherapy in human and veterinary medicine. Vet Dermatol 2009; 20 (02) 84-98
    CrossrefPubMedGoogle Scholar
  • 33 Willemse A. Canine atopic disease: investigations of eosinophils and the nasal mucosa. Am J Vet Res 1984; 45 (09) 1867-1869
    PubMedGoogle Scholar
  • 34 Schnabl B, Bettenay SV, Dow K. et al. Results of allergen-specific immunotherapy in 117 dogs with atopic dermatitis. Vet Rec 2006; 158 (03) 81-85
    CrossrefPubMedGoogle Scholar
  • 35 Hobi S, Mueller RS. Efficacy and safety of rush immunotherapy with alum-precipitated allergens in canine atopic dermatitis. Tierarztl Prax Ausg K Kleintiere Heimtiere 2014; 42 (03) 167-173
    PubMedGoogle Scholar
  • 36 Lian TM, Halliwell RE. Allergen-specific IgE and IgGd antibodies in atopic and normal dogs. Vet Immunol Immunopathol 1998; 66(3 – 4): 203-223
    CrossrefPubMedGoogle Scholar
  • 37 Aalberse RC, Koshte V, Clemens JG. Immunoglobulin E antibodies that crossreact with vegetable foods, pollen, and Hymenoptera venom. J Allergy Clin Immunol 1981; 68 (05) 356-364
    CrossrefPubMedGoogle Scholar
  • 38 Altmann F. Coping with cross-reactive carbohydrate determinants in allergy diagnosis. Allergo J Int 2016; 25 (04) 98-105
    CrossrefPubMedGoogle Scholar
  • 39 Levy BJ, DeBoer DJ. A preliminary study of serum IgE against cross-reactive carbohydrate determinants (CCD) in client-owned atopic dogs. Vet Dermatol 2018; 29 (03) 243-e90
    PubMedGoogle Scholar
  • 40 Mueller RS, Bettenay SV. Evaluation of the safety of an abbreviated course of injections of allergen extracts (rush immunotherapy) for the treatment of dogs with atopic dermatitis. Am J Vet Res 2001; 62 (03) 307-310
    CrossrefPubMedGoogle Scholar
  • 41 Mueller RS, Veir J, Fieseler KV. et al. Use of immunostimulatory liposome-nucleic acid complexes in allergen-specific immunotherapy of dogs with refractory atopic dermatitis – a pilot study. Vet Dermatol 2005; 16 (01) 61-68
    CrossrefPubMedGoogle Scholar
  • 42 Griffin CE, Hillier A. The ACVD task force on canine atopic dermatitis (XXIV): allergen-specific immunotherapy. Vet Immunol Immunopathol 2001; 81(3 – 4): 363-383
    CrossrefPubMedGoogle Scholar
  • 43 Timm K, Mueller RS, Nett-Mettler CS. Long-term effects of intralymphatic immunotherapy (ILIT) on canine atopic dermatitis. Vet Dermatol 2018; 29 (02) 123-e49
    PubMedGoogle Scholar
  • 44 DeBoer DJ, Verbrugge M, Morris M. Clinical and immunological responses of dust mite sensitive, atopic dogs to treatment with sublingual immunotherapy (SLIT). Vet Dermatol 2016; 27 (02) 82-87 e23
    CrossrefPubMedGoogle Scholar
  • 45 Fischer N, Rostaher A, Favrot C. Intralymphatic immunotherapy: An effective and safe alternative route for canine atopic dermatitis. Schweiz Arch Tierheilkd 2016; 158 (09) 646-652
    CrossrefPubMedGoogle Scholar
  • 46 DeBoer DJ. The future of immunotherapy for canine atopic dermatitis: a review. Vet Dermatol 2017; 28 (01) 25-e6
    CrossrefPubMedGoogle Scholar
  • 47 Kawano K, Mizuno T. A pilot study of the effect of pullulan-conjugated Der f 2 allergen-specific immunotherapy on canine atopic dermatitis. Vet Dermatol 2017; 28 (06) 583-e141
    PubMedGoogle Scholar
  • 48 Olivry T, Paps JS, Dunston SM. Proof of concept of the preventive efficacy of high-dose recombinant mono-allergen immunotherapy in atopic dogs sensitized to the Dermatophagoides farinae allergen Der f 2. Vet Dermatol 2017; 28 (02) 183-e40
    PubMedGoogle Scholar
  • 49 Fischer N, Tarpataki N, Leidi F. et al. An open study on the efficacy of a recombinant Der f 2 (Dermatophagoides farinae) immunotherapy in atopic dogs in Hungary and Switzerland. Vet Dermatol 2018; DOI: 10.1111/vde.12657.
    CrossrefPubMedGoogle Scholar
  • 50 Wagner I, Geh KJ, Hubert M. et al. Preliminary evaluation of cytosine-phosphate-guanine oligodeoxynucleotides bound to gelatine nanoparticles as immunotherapy for canine atopic dermatitis. Vet Rec 2017; 181 (05) 118
    CrossrefPubMedGoogle Scholar